Replies to post #2261 on BioCurex, Inc.(fka BOCX)

[Kag]

Rajacat,
This is a very good find on your part with a February 14, 2006 date. Please send the same link that you posted, in an email along with a note, to Dr. Moro at BioCurex. Many times CEO's are so busy that they don't quickly get to see these things. This sure appears to apply to the RECAF technology. Imaging especially,and focus on this statement. "Critical Path is the FDA's premier initiative to identify and prioritize the most pressing medical product development problems and the greatest opportunities for rapid improvement in public health benefits."
This could put at some of the RECAF technology on what the FDA generally refers to as "fast Track." kag